• Applied Workflows with Recombinant Human EGF: Migration, Pro

  2026-05-03

  Recombinant human Epidermal Growth Factor (EGF) enables precise, reproducible modulation of cell proliferation and migration, with proven applications in cancer cell biology and mucosal healing. This article delivers validated protocols, advanced troubleshooting, and actionable insights from the latest research, maximizing the impact of APExBIO’s high-purity EGF for experimental success.

• SMYD2 Inhibition Alleviates Cisplatin-Induced Renal Fibrosis

  2026-05-02

  This study demonstrates that pharmacological inhibition of SMYD2, using small molecules such as LLY-507, protects against cisplatin-induced renal fibrosis and inflammation in a chronic kidney disease (CKD) model. The findings reveal SMYD2 as a promising therapeutic target for preventing fibrosis, with implications for both renal and broader fibrotic disease research.

• Technical Use of Neuromedin S (rat) in GPCR Assays

  2026-05-02

  Neuromedin S (rat) is a chemically defined, endogenous peptide agonist for targeted activation of neuromedin U receptor pathways in controlled laboratory research. It is optimized for GPCR/G protein signaling studies, particularly in rat-based models of energy homeostasis and stress response. This product is not appropriate for diagnostic or therapeutic applications and requires strict adherence to solubility and storage protocols to ensure reproducibility.

• Clathrin-Mediated Endocytosis Drives Grass Carp Reovirus Ent

  2026-05-01

  Wang et al. (2018) provide compelling evidence that genotype III grass carp reovirus (GCRV104) enters host cells via clathrin-mediated endocytosis, a process independent of actin cytoskeleton disruption. These findings clarify the viral entry pathway and inform the design of mechanistic studies in aquatic virology and cell biology.

• Lumiracoxib: Selective COX-2 Inhibitor for Muscle Injury Mod

  2026-04-30

  Lumiracoxib empowers researchers to dissect COX-2’s roles in inflammation and vascular repair with high selectivity and robust solubility. This guide details actionable workflows, troubleshooting strategies, and interpretive angles for applying Lumiracoxib in advanced muscle injury models.

• Ruxolitinib Phosphate: Strategic Advances in JAK/STAT Modula

  2026-04-30

  This article offers translational researchers a thought-leadership perspective on Ruxolitinib phosphate (INCB018424), highlighting its mechanistic impact on the JAK/STAT signaling pathway and its evolving role in oncology and autoimmune disease models. Drawing from recent primary research and practical workflow insights, we explore how Ruxolitinib phosphate, as supplied by APExBIO, is redefining the landscape of cytokine signaling inhibition, mitochondrial dynamics, and cell death modalities. The discussion sets a new benchmark for integrating mechanistic discovery with strategic experimental design, and concludes with a forward-looking outlook on clinical and translational innovation.

• L-NAME Hydrochloride: Optimizing NOS Inhibition for Vascular

  2026-04-29

  L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) is the gold standard NOS inhibitor for dissecting nitric oxide-driven mechanisms in vascular tone regulation and inflammation research. This article unpacks optimized protocols, practical troubleshooting, and translational insights—bridging cellular, animal, and anti-inflammatory workflows for cardiovascular disease models.

• Pregnenolone-16α-carbonitrile Suppresses Hippocampal CYP and

  2026-04-29

  This study reveals that Pregnenolone-16α-carbonitrile (PCN) can suppress hippocampal cytochrome P450 enzymes and reduce phenytoin-induced neurotoxicity via a glucocorticoid receptor-dependent, but PXR-independent, pathway. These findings challenge canonical assumptions about PCN's mechanism and highlight novel regulatory axes in neuroprotection.

• Cyclic Pifithrin-α Hydrobromide: Precision Tools for p53 Pat

  2026-04-28

  Discover how Cyclic Pifithrin-α hydrobromide, a potent p53 inhibitor, enables advanced mapping of p53 signaling and apoptosis inhibition in cancer research. This article uncovers new translational insights and practical protocols, differentiating from existing guides with a deeper focus on neuroinflammatory assay design.

• Annexin V-FITC/PI Apoptosis Assay Kit: Innovations & Next-Ge

  2026-04-28

  Discover how the Annexin V-FITC/PI Apoptosis Assay Kit enables precise early apoptosis detection and advanced analysis in infectious disease and wound healing research. This in-depth article uniquely bridges cell death quantification with the latest nano-delivery and photodynamic therapy innovations.

• BMN 673 (Talazoparib): Potency & Mechanism in PARP1/2 Inhibi

  2026-04-27

  BMN 673 (Talazoparib) is a highly selective PARP1/2 inhibitor with nanomolar potency, optimized for DNA repair deficiency targeting and homologous recombination-deficient cancer research. Its unique mechanism of PARP-DNA complex trapping and efficacy in BRCA2-deficient models make it a benchmark tool for synthetic lethality studies and small cell lung cancer research.

• Fluconazole in Biofilm Drug Resistance: Translational Insigh

  2026-04-27

  This thought-leadership article examines the evolving role of Fluconazole as a fungal cytochrome P450 enzyme 14α-demethylase inhibitor in unraveling the molecular underpinnings of Candida albicans biofilm resistance. Integrating evidence from cutting-edge research, it provides mechanistic context, experimental best practices, and strategic guidance for translational researchers, while highlighting the critical interplay between autophagy, ergosterol biosynthesis inhibition, and antifungal susceptibility testing. The article distinguishes itself by bridging mechanistic discovery and actionable workflow recommendations, positioning APExBIO’s Fluconazole as an indispensable tool for advancing next-generation antifungal research.

• CXCL1-CXCR2 Signaling Drives NTS Microglia in Pancreatic Pai

  2026-04-26

  This paper elucidates how CXCL1-CXCR2 signaling in the nucleus tractus solitarii (NTS) activates microglia, promoting abdominal pain in pancreatic cancer. The findings define a central neuroimmune mechanism underlying cancer-induced pain, with implications for targeted therapeutic development.

• Praeruptorin A: Angular Pyranocoumarin Compound for Inflamma

  2026-04-25

  Praeruptorin A, a multi-targeted angular pyranocoumarin compound, redefines anti-inflammatory and cancer research by enabling robust, pathway-specific modulation in preclinical models. Its unique inhibition of STAT-1/3 and barrier-repair mechanisms unlock new experimental workflows for ulcerative colitis and beyond.

• Streptavidin-FITC: Unlocking Intracellular Insights for Tran

  2026-04-24

  This article advances the field by integrating mechanistic insight on lipid nanoparticle (LNP) intracellular trafficking with strategic, workflow-oriented guidance for translational researchers utilizing Streptavidin-FITC. Building on the latest peer-reviewed evidence and scenario-driven best practices, it delivers a nuanced perspective on how fluorescein isothiocyanate conjugated streptavidin empowers robust biotin-streptavidin binding assays and high-sensitivity detection across immunohistochemistry, flow cytometry, and nucleic acid delivery applications. The article positions APExBIO’s Streptavidin-FITC as a benchmark reagent for overcoming delivery bottlenecks and driving innovation in clinical and translational research.

459 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page